Display options
Cite
D'Amelio R, Asero R, Cassatella MA, et al. Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines. 2021;9(9)doi: 10.3390/biomedicines9091163.
D'Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., Senna, G., Vacca, A., & Maggi, E. (2021). Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines, 9(9), . https://doi.org/10.3390/biomedicines9091163
D'Amelio, Raffaele, et al. "Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies." Biomedicines vol. 9,9 (2021). doi: https://doi.org/10.3390/biomedicines9091163
D'Amelio R, Asero R, Cassatella MA, Laganà B, Lunardi C, Migliorini P, Nisini R, Parronchi P, Quinti I, Racanelli V, Senna G, Vacca A, Maggi E. Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines. 2021 Sep 04;9(9). doi: 10.3390/biomedicines9091163. PMID: 34572349; PMCID: PMC8465958.
Copy Download .nbib Format: NLM
Share it on

Biomedicines. 2021 Sep 04;9(9). doi: 10.3390/biomedicines9091163.

Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies.

Biomedicines

Raffaele D'Amelio, Riccardo Asero, Marco Antonio Cassatella, Bruno Laganà, Claudio Lunardi, Paola Migliorini, Roberto Nisini, Paola Parronchi, Isabella Quinti, Vito Racanelli, Gianenrico Senna, Angelo Vacca, Enrico Maggi

Affiliations

  1. Dipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
  2. Ambulatorio di Allergologia, Clinica S. Carlo di Paderno Dugnano, Via Ospedale 21, 20037 Milano, Italy.
  3. Sezione di Patologia Generale, Dipartimento di Medicina, Università di Verona, Strada Le Grazie 4, 37134 Verona, Italy.
  4. UOC Medicina Interna, Dipartimento di Medicina Clinica e Molecolare, AOU S. Andrea, Sapienza Università di Roma, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
  5. Responsabile Unità di Malattie Autoimmunitarie, Dipartimento di Medicina, AOU Policlinico G.B. Rossi, Borgo Roma, Università di Verona, Piazzale Ludovico Antonio Scuro 10, 37134 Verona, Italy.
  6. Direttore Unità Operativa di Immunoallergologia Clinica, Dipartimento di Medicina Clinica e Sperimentale, Azienda Ospedaliero Universitaria Pisana, Università di Pisa, Via Roma 67, 56126 Pisa, Italy.
  7. Direttore Reparto Immunologia, Dipartimento di Malattie Infettive, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
  8. Direttore SOD Immunologia e Terapie Cellulari, Dipartimento di Medicina Sperimentale e Clinica, AOU Careggi, Università di Firenze, Largo Brambilla 3, 50134 Firenze, Italy.
  9. Responsabile UOD Centro di Riferimento Regionale per le Immunodeficienze, Dipartimento di Medicina Molecolare, AOU Policlinico Umberto I, Sapienza Università di Roma, Viale dell'Università 37, 00161 Rome, Italy.
  10. UOC Medicina Interna "Guido Baccelli", Dipartimento di Scienze Biomediche ed Oncologia Umana, AOU Policlinico, Università di Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy.
  11. Direttore USD Allergologia, Dipartimento di Medicina, AOU Policlinico G.B. Rossi, Borgo Roma, Università di Verona, Piazzale Ludovico Antonio Scuro 10, 37134 Verona, Italy.
  12. Direttore UOC Medicina Interna "Guido Baccelli", Dipartimento di Scienze Biomediche ed Oncologia Umana, AOU Policlinico, Università di Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy.
  13. Unità di Immunità Traslazionale, Dipartimento di Immunologia, Ospedale Pediatrico Bambino Gesù, IRCCS, Viale di S. Paolo 15, 00146 Rome, Italy.

PMID: 34572349 PMCID: PMC8465958 DOI: 10.3390/biomedicines9091163

Abstract

The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western countries. Brand new anti-COVID-19 vaccines have been developed and made available in <1-year from the viral sequence publication. Patients with compromised immune systems, such as autoimmune-autoinflammatory disorders (AIAIDs), primary (PIDs) and secondary (SIDs) immunodeficiencies, have received careful attention for a long time regarding their capacity to safely respond to traditional vaccines. The Italian Immunological Societies, therefore, have promptly faced the issues of safety, immunogenicity, and efficacy/effectiveness of the innovative COVID-19 vaccines, as well as priority to vaccine access, in patients with AIADs, PIDs, and SIDs, by organizing an ad-hoc Task Force. Patients with AIADs, PIDs, and SIDs: (1) Do not present contraindications to COVID-19 vaccines if a mRNA vaccine is used and administered in a stabilized disease phase without active infection. (2) Should usually not discontinue immunosuppressive therapy, which may be modulated depending on the patient's clinical condition. (3) When eligible, should have a priority access to vaccination. In fact, immunizing these patients may have relevant social/health consequences, since these patients, if infected, may develop chronic infection, which prolongs viral spread and facilitates the emergence of viral variants.

Keywords: COVID-19; SARS-CoV-2; auto-immune auto-inflammatory disorders; primary immunodeficiencies; secondary immunodeficiencies; vaccines

References

  1. Lancet. 2021 Jul 17;398(10296):213-222 - PubMed
  2. JAMA. 2021 Jun 22;325(24):2448-2456 - PubMed
  3. Front Immunol. 2019 Aug 07;10:1883 - PubMed
  4. Lancet. 2021 Jun 26;397(10293):2461-2462 - PubMed
  5. Cell. 2021 May 27;184(11):2939-2954.e9 - PubMed
  6. J Clin Invest. 2021 Jul 15;131(14): - PubMed
  7. Vaccine. 2018 Jun 7;36(24):3541-3554 - PubMed
  8. JAMA Cardiol. 2021 Jun 29;: - PubMed
  9. Ann Rheum Dis. 2020 Jan;79(1):39-52 - PubMed
  10. N Engl J Med. 2021 Jul 15;385(3):239-250 - PubMed
  11. Nat Commun. 2021 Mar 2;12(1):1386 - PubMed
  12. Ann Rheum Dis. 2021 Oct;80(10):1357-1359 - PubMed
  13. Immunotherapy. 2020 Jun;12(8):571-576 - PubMed
  14. Emerg Microbes Infect. 2021 Dec;10(1):629-637 - PubMed
  15. Nature. 2020 Oct;586(7830):578-582 - PubMed
  16. Ann Rheum Dis. 2021 Oct;80(10):1312-1316 - PubMed
  17. N Engl J Med. 2020 Oct 15;383(16):1544-1555 - PubMed
  18. Lancet. 2021 Jan 9;397(10269):99-111 - PubMed
  19. Vaccine. 2016 Apr 12;34(17):2008-14 - PubMed
  20. N Engl J Med. 2021 Jun 10;384(23):2187-2201 - PubMed
  21. N Engl J Med. 2021 Jul 8;385(2):187-189 - PubMed
  22. Vaccine. 2020 Nov 25;38(50):7892-7896 - PubMed
  23. Rev Med Interne. 2017 Sep;38(9):603-613 - PubMed
  24. JAMA. 2021 May 18;325(19):2013-2014 - PubMed
  25. Ann Allergy Asthma Immunol. 2021 Sep;127(3):383-384 - PubMed
  26. Lancet Respir Med. 2021 Aug 12;: - PubMed
  27. JAMA. 2021 Apr 6;325(13):1241-1243 - PubMed
  28. Front Immunol. 2021 Jun 16;12:704773 - PubMed
  29. Vaccine. 2016 Jan 20;34(4):413-423 - PubMed
  30. Biomedicines. 2021 Jan 17;9(1): - PubMed
  31. Int Rev Immunol. 2010 Jun;29(3):270-314 - PubMed
  32. J Clin Invest. 2021 Jun 15;131(12): - PubMed
  33. N Engl J Med. 2021 Aug 12;385(7):661-662 - PubMed
  34. Ann Rheum Dis. 2021 Oct;80(10):1351-1352 - PubMed
  35. JAMA. 2021 Apr 20;325(15):1535-1544 - PubMed
  36. Nat Commun. 2021 May 11;12(1):2670 - PubMed
  37. JAMA. 2021 Jun 15;325(23):2370-2380 - PubMed
  38. Nature. 2021 May;593(7860):491 - PubMed
  39. J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4 - PubMed
  40. MMWR Recomm Rep. 2000 Oct;49(RR-10):1-125, CE1-7 - PubMed
  41. Vaccine. 2017 Mar 1;35(9):1216-1226 - PubMed
  42. PLoS Med. 2018 Nov 1;15(11):e1002685 - PubMed
  43. J Korean Med Sci. 2021 Mar 29;36(12):e95 - PubMed
  44. Ann Rheum Dis. 2021 Oct;80(10):1361-1362 - PubMed
  45. J Allergy Clin Immunol. 2021 Mar;147(3):870-875.e1 - PubMed
  46. Sci Transl Med. 2021 Jan 20;13(577): - PubMed
  47. N Engl J Med. 2021 Mar 8;384(15):1466-1468 - PubMed
  48. Expert Rev Clin Immunol. 2021 Feb;17(2):163-168 - PubMed
  49. Clin Immunol. 2018 Oct;195:18-27 - PubMed
  50. Science. 2021 Apr 9;372(6538): - PubMed
  51. Dermatol Ther. 2021 Jan;34(1):e14627 - PubMed
  52. Rheumatology (Oxford). 2021 Apr 12;: - PubMed
  53. N Engl J Med. 2021 Jun 17;384(24):2273-2282 - PubMed
  54. Ann Rheum Dis. 2021 Oct;80(10):1355-1356 - PubMed
  55. J Allergy Clin Immunol. 2021 Sep;148(3):739-749 - PubMed
  56. J Gen Virol. 2007 Oct;88(Pt 10):2740-2748 - PubMed
  57. N Engl J Med. 2021 Sep 23;385(13):1172-1183 - PubMed
  58. Lancet. 2021 Feb 20;397(10275):671-681 - PubMed
  59. Ann Rheum Dis. 2021 Oct;80(10):1339-1344 - PubMed
  60. Ann Rheum Dis. 2021 Oct;80(10):1330-1338 - PubMed
  61. Lancet. 2020 Sep 26;396(10255):887-897 - PubMed
  62. Blood Transfus. 2021 May 27;: - PubMed
  63. N Engl J Med. 2021 Jun 10;384(23):2202-2211 - PubMed
  64. Science. 2021 May 21;372(6544):815-821 - PubMed
  65. Pathog Immun. 2021 Jun 7;6(1):116-134 - PubMed
  66. J Allergy Clin Immunol. 2021 Feb;147(2):520-531 - PubMed
  67. Vaccine. 2011 Feb 11;29(8):1643-8 - PubMed
  68. N Engl J Med. 2021 Feb 4;384(5):403-416 - PubMed
  69. Ann Rheum Dis. 2021 Mar 19;: - PubMed
  70. Lancet Glob Health. 2021 Jul;9(7):e1017-e1021 - PubMed
  71. Lancet. 2020 Jun 13;395(10240):1845-1854 - PubMed
  72. Clin Exp Immunol. 2020 Nov;202(2):162-192 - PubMed
  73. N Engl J Med. 2020 Dec 10;383(24):2320-2332 - PubMed
  74. N Engl J Med. 2021 Feb 18;384(7):643-649 - PubMed
  75. Nature. 2021 May;593(7858):270-274 - PubMed
  76. Nat Biotechnol. 2020 May;38(5):523-532 - PubMed
  77. Inflamm Intest Dis. 2018 Nov;3(1):11-15 - PubMed
  78. Lancet Oncol. 2021 Jun;22(6):765-778 - PubMed
  79. Lancet. 2021 May 29;397(10289):2043-2046 - PubMed
  80. Cochrane Database Syst Rev. 2018 Feb 01;2:CD008983 - PubMed
  81. Ann Rheum Dis. 2021 Oct;80(10):e162 - PubMed
  82. J Clin Invest. 2021 May 17;131(10): - PubMed
  83. Immunotherapy. 2015;7(12):1273-92 - PubMed
  84. Lancet Infect Dis. 2021 Feb;21(2):181-192 - PubMed
  85. Cell Rep Med. 2020 Oct 20;1(7):100126 - PubMed
  86. Lancet. 2021 Dec 19;396(10267):1979-1993 - PubMed
  87. RMD Open. 2019 Sep 9;5(2):e001035 - PubMed
  88. Ann Rheum Dis. 2021 Feb 9;: - PubMed
  89. J Transl Med. 2014 Mar 22;12:77 - PubMed
  90. N Engl J Med. 2021 May 20;384(20):1899-1909 - PubMed
  91. N Engl J Med. 2021 Sep 9;385(11):1049-1051 - PubMed
  92. N Engl J Med. 2021 Aug 12;385(7):585-594 - PubMed
  93. N Engl J Med. 2021 Mar 17;384(15):1468-1470 - PubMed
  94. Lancet Infect Dis. 2021 Jul;21(7):950-961 - PubMed
  95. Am J Hematol. 2021 May 1;96(5):534-537 - PubMed
  96. Clin Infect Dis. 2014 Feb;58(3):309-18 - PubMed
  97. Intern Med J. 2021 May;51(5):763-768 - PubMed
  98. Arthritis Rheumatol. 2021 Aug;73(8):e30-e45 - PubMed
  99. Front Immunol. 2021 Apr 15;12:656362 - PubMed
  100. Ann Rheum Dis. 2020 Oct 13;: - PubMed
  101. Ann Rheum Dis. 2021 Oct;80(10):1306-1311 - PubMed
  102. Radiol Case Rep. 2021 Aug;16(8):2142-2145 - PubMed
  103. Science. 2021 Mar 25;: - PubMed
  104. Nature. 2021 Jul;595(7867):426-431 - PubMed
  105. Lancet Infect Dis. 2021 Jun 28;: - PubMed
  106. Nature. 2021 May;593(7857):136-141 - PubMed
  107. N Engl J Med. 2020 Dec 3;383(23):2291-2293 - PubMed
  108. N Engl J Med. 2021 May 20;384(20):1885-1898 - PubMed
  109. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  110. Nat Commun. 2021 May 17;12(1):2893 - PubMed
  111. Semin Arthritis Rheum. 2015 Oct;45(2):190-4 - PubMed
  112. JAMA. 2021 Jun 1;325(21):2204-2206 - PubMed
  113. Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2 - PubMed
  114. Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342 - PubMed
  115. N Engl J Med. 2021 Jul 22;385(4):320-329 - PubMed

Publication Types